Nanalyze July 24, 2021
Earlier this year, we picked apart the 23andMe stock offering for genetic testing. The financial picture looked stagnant, with 23andMe (ME) trying to build interest in the company’s FDA-authorized health insights and a subscription service that provides access to additional reports as they become available. As we noted in the article, the company’s most valuable asset is its genetics database. Pharmaceutical companies like GlaxoSmithKline (GSK), which invested $300 million in 23andMe about three years ago, can leverage the genetics data from millions of people to develop more precise therapeutics in areas like oncology and cardiovascular disease. But the genetic tests from 23andMe and other DNA companies only scratch the surface of what we can learn about hereditary conditions like cancer...
Today's Sponsors
Today's Sponsor